Sartorius Launches Next-Generation Platform to Boost Efficiency in Cell Therapy Production

Rhea-AI Summary

Sartorius (OTC:SARTF) launched the Eveo Cell Therapy Platform on March 16, 2026, an integrated, modular system for automated, multi-parallel production and QC of autologous cell therapies. The compact platform can process eight patient batches in the cleanroom space typically used for two, enabling ~350 doses/year versus ~100 today and modeling a ~90% manufacturing cost reduction for CAR-T workflows. A successful pilot with CDMO ElevateBio demonstrated applicability. Orders begin September 2026 with first deliveries expected in 2027.

Positive

• Output ~4x: ~350 doses/year in footprint that today yields ~100
• Cost reduction ~90% in modeled CAR-T manufacturing costs
• Operator efficiency: one operator can process 8 patient batches vs 2
• ElevateBio pilot validated real-world applicability

Negative

• Industry bottlenecks: ~60% of regulatory disruptions stem from manufacturing/process issues
• Commercial timing gap: orders start Sept 2026 with first deliveries in 2027

Key Figures

Output increase: up to fourfold Cost reduction: 90 percent Regulatory disruptions share: 60 percent +5 more

8 metrics

Output increase up to fourfold Eveo platform output in existing cleanroom space

Cost reduction 90 percent Potential manufacturing cost reduction in CAR-T processes

Regulatory disruptions share 60 percent Regulatory disruptions in cell therapy production caused by manufacturing/process issues

Parallel batches 8 patient batches Single operator capacity in multi-parallel configuration

Manufacturing time around seven days Manufacturing time per batch assumption

Production weeks 50 weeks per year Production schedule assumption

Annual doses with Eveo more than 350 doses Projected yearly doses vs roughly 100 doses currently

Sales revenue around 3.5 billion euros Company sales revenue in 2025

Market Reality Check

Price: $226.33 Vol: Volume 5 is 85% below the...

low vol

$226.33 Last Close

Volume Volume 5 is 85% below the 20-day average of 33, indicating limited participation. low

Technical Trading at 226.33, modestly above the 200-day MA of 220, after prior weakness vs 52-week high (-27.69%).

Peers on Argus

Peers show mixed moves: key ADRs are down (e.g., SDMHF -2.01%, SOAGY -3.12%) whi...

Peers show mixed moves: key ADRs are down (e.g., SDMHF -2.01%, SOAGY -3.12%) while SSSGY is slightly up (+0.49%). This divergence versus SARTF’s modest gain suggests a stock-specific reaction rather than a broad sector move.

Market Pulse Summary

This announcement highlights Sartorius’ Eveo Cell Therapy Platform, designed to boost autologous cel...

Analysis

This announcement highlights Sartorius’ Eveo Cell Therapy Platform, designed to boost autologous cell therapy output up to fourfold and potentially cut CAR-T manufacturing costs by around 90%. It addresses manufacturing issues linked to roughly 60% of regulatory disruptions and targets more than 350 annual doses in space that currently yields about 100. With orders planned from September 2026 and first deliveries in 2027, investors may watch adoption, partner traction, and future updates on commercialization milestones.

Key Terms

autologous cell therapies, CAR-T therapies, CDMO, cleanroom, +4 more

8 terms

autologous cell therapies medical

"integrated system for the production and quality control (QC) of autologous cell therapies."

Therapies that use a patient’s own cells as the medicine, harvesting, modifying or expanding those cells outside the body and then returning them to treat disease. They matter to investors because using a patient’s own material can reduce rejection risk but creates high costs, complex manufacturing and individualized logistics—think of it like a custom-tailored treatment rather than a factory-made pill—affecting pricing, scalability and regulatory hurdles.

CAR-T therapies medical

"limit scalability and patient access to transformative treatments such as CAR-T therapies."

CAR-T therapies are cancer treatments that reprogram a patient’s own immune cells to recognize and attack tumors, like turning ordinary soldiers into guided missiles aimed at specific cancer markers. They matter to investors because they can offer dramatic, long-lasting benefits for hard-to-treat cancers but involve high research and manufacturing costs, complex logistics, regulatory scrutiny, and pricing debates that can drive significant commercial upside or downside.

CDMO technical

"Sartorius has collaborated with ElevateBio, a leading cell therapy CDMO, amongst other partners,"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

cleanroom technical

"a single operator can process eight patient batches at once in the same cleanroom space"

A cleanroom is a tightly controlled workspace where air, particles, microbes, temperature and humidity are kept within strict limits to prevent contamination during manufacturing, testing or research—commonly used for pharmaceuticals, biotech, medical devices and semiconductors. Investors care because a well-designed and operated cleanroom reduces product defects, supports regulatory approval and enables reliable scale-up; think of it as a sterile kitchen that protects delicate recipes, lowering recall risk and helping preserve revenue and margins.

flow cytometry medical

"capabilities in live cell imaging and high throughput flow cytometry included in the Eveo platform,"

A laboratory method that uses lasers and sensors to count and analyze individual cells or tiny particles as they flow past a detector, like a high‑speed supermarket scanner that reads barcodes on each item. Investors care because flow cytometry is widely used in drug development, diagnostics and manufacturing quality control; demand for the instruments, reagents and services can signal progress in clinical programs, recurring revenue streams and adoption of new therapies or tests.

single-use solutions technical

"broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production"

Single-use solutions are medical products or consumables designed to be used once and then discarded, like disposable syringes, catheters, or sterile procedure kits. For investors they matter because they create steady, repeatable demand, can simplify manufacturing and regulatory hurdles compared with reusable devices, and influence profit margins, supply-chain risk and recurring revenue potential—similar to how disposable paper plates create ongoing sales versus one durable set of dishes.

quality control technical

"integrated system for the production and quality control (QC) of autologous cell therapies."

Quality control is the set of checks and processes a company uses to make sure its products, services, or data meet consistent standards before they reach customers or regulators. Like a final inspection on an assembly line, it reduces the chance of costly errors, recalls, fines, or reputation damage, so investors look at it to judge how reliable a company’s operations, future costs, and revenue stability are likely to be.

bioreactors technical

"using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies."

A bioreactor is a controlled vessel where living cells or microorganisms are grown to produce medicines, vaccines, enzymes, or other biological materials; think of it as an industrial kitchen that provides the right ingredients, temperature and conditions so the ‘recipe’ can be made reliably. Investors care because a company’s bioreactor capacity, efficiency and regulatory compliance determine how much product can be made, the cost per dose or unit, and how quickly a developer can scale revenue or respond to demand and safety issues.

AI-generated analysis. Not financial advice.

GOTTINGEN, GERMANY / ACCESS Newswire / March 16, 2026 / Sartorius launches next-generation platform to boost efficiency in cell therapy production

• Eveo Cell Therapy Platform enables automated, multi-parallel intensified production of autologous cell therapies

• Compact design can increase output up to fourfold in existing cleanroom space

• 90 percent reduction in manufacturing costs possible in CAR-T processes

• Successful pilot project with CDMO ElevateBio proves applicability

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR-T therapies. With its latest innovation, Sartorius introduces a fundamentally new approach to cell therapy production that strengthens the company's position in the dynamic advanced therapies market.

"Cell therapies are redefining medical possibilities. Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on," said René Fáber, member of the Executive Board at Sartorius. "By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients."

Conventional manufacturing models for autologous cell therapies rely on centralized, purpose-built facilities, that require significant greenfield investment, staff recruitment, training and multi-year build-up phases. Nevertheless, around 60 percent of regulatory disruptions in cell therapy production are caused by manufacturing and process-related issues.

The new Eveo platform addresses these challenges by integrating cell selection, activation, gene modification, expansion, wash and concentration and final formulation into a closed system, using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies. The system's compact design supports implementation in existing facilities with existing staff, allows for operation in lower-classification environments and supports centralized and decentralized manufacturing models.

Sartorius has collaborated with ElevateBio, a leading cell therapy CDMO, amongst other partners, to test out the Eveo platform. In a successful pilot, the system performed in line with design expectations, demonstrating its real-world applicability. Due to its multi-parallel configuration, a single operator can process eight patient batches at once in the same cleanroom space traditionally needed for two batches. Assuming a manufacturing time of around seven days per batch and 50 production weeks per year, Eveo enables production of more than 350 doses per year in a footprint that today yields roughly 100 doses - an almost fourfold increase. Financial modelling confirms that the platform can reduce manufacturing costs by around 90 percent.

Quality control also represents a major bottleneck in cell therapy production and release. With Sartorius' capabilities in live cell imaging and high throughput flow cytometry included in the Eveo platform, the technology addresses key analytical challenges and enables accessibility.

Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for use with its manufacturing customers.

More information about Eveo Cell Therapy Platform
www.sartorius.com/en/pr/eveo-cell-therapy-platform

A profile of Sartorius

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.

Visit our newsroom and follow us on LinkedIn.

Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com

SOURCE: SARTORIUS AG

View the original press release on ACCESS Newswire

FAQ

When will Sartorius (SARTF) accept orders and deliver the Eveo Cell Therapy Platform?

Sartorius will start taking orders in September 2026, with first deliveries expected in 2027. According to the company, the timeline positions Eveo for commercial deployment next year with pilot access already granted to ElevateBio.

How much production increase does the Eveo platform deliver for cell therapy manufacturers?

Eveo can increase output nearly fourfold, from ~100 to ~350 doses per year in the same footprint. According to the company, multi-parallel processing lets one operator run eight patient batches simultaneously versus two today.

What manufacturing cost savings does Sartorius claim for CAR-T using Eveo (SARTF)?

Sartorius models about a 90% reduction in CAR-T manufacturing costs using Eveo. According to the company, integrated automation, parallelization, and compact design drive large per-dose cost decreases in their financial modelling.

Did ElevateBio test the Eveo platform and what were the results?

ElevateBio participated in a pilot that the company describes as successful and in line with design expectations. According to Sartorius, the pilot demonstrated Eveo's real-world applicability for CDMO manufacturing customers.

How does Eveo address QC and analytical bottlenecks in cell therapy production?

Eveo integrates live cell imaging and high-throughput flow cytometry to streamline QC and release testing. According to the company, these built-in analytics tackle key assay throughput and accuracy constraints in autologous workflows.